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Abstract
Background:  Both raloxifene and bisphosphonates are indicated for the prevention and treatment of
postmenopausal osteoporosis, however these medications have different efficacy and safety profiles. It is plausible
that physicians would prescribe these agents to optimize the benefit/risk profile for individual patients. The
objective of this study was to compare demographic and clinical characteristics of patients initiating raloxifene
with those of patients initiating bisphosphonates for the prevention and treatment of osteoporosis.
Methods: This study was conducted using a retrospective cohort design. Female beneficiaries (45 years and
older) with at least one claim for raloxifene or a bisphosphonate in 2003 through 2005 and continuous enrollment
in the previous 12 months and subsequent 6 months were identified using a collection of large national
commercial, Medicare supplemental, and Medicaid administrative claims databases (MarketScan®). Patients were
divided into two cohorts, a combined commercial/Medicare cohort and a Medicaid cohort. Within each cohort,
characteristics (demographic, clinical, and resource utilization) of patients initiating raloxifene were compared to
those of patients initiating bisphosphonate therapy. Group comparisons were made using chi-square tests for
proportions of categorical measures and Wilcoxon rank-sum tests for continuous variables. Logistic regression
was used to simultaneously examine factors independently associated with initiation of raloxifene versus a
bisphosphonate.
Results: Within both the commercial/Medicare and Medicaid cohorts, raloxifene patients were younger, had
fewer comorbid conditions, and fewer pre-existing fractures than bisphosphonate patients. Raloxifene patients in
both cohorts were less likely to have had a bone mineral density (BMD) screening in the previous year than were
bisphosphonate patients, and were also more likely to have used estrogen or estrogen/progestin therapy in the
previous 12 months. These differences remained statistically significant in the multivariate model.
Conclusion: In this sample of patients enrolled in commercial, Medicare, and Medicaid plans, patients who
initiated raloxifene treatment differed from those initiating bisphosphonates. Raloxifene patients were younger,
had better overall health status and appeared to be less likely to have risk factors for new osteoporotic fractures
than bisphosphonate patients. Differences in the clinical profiles of these agents may impact prescribing decisions.
Investigators using observational data to make comparisons of treatment outcomes associated with these
medications should take these important differences in patient characteristics into consideration.
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Background
Osteoporosis is the most common bone disease in the
United States, affecting approximately 10 million people
over the age of 50 [1]. An additional 18 million individu-
als have osteopenia, a precursor of osteoporosis [2]. Oste-
oporosis contributes to more than 1.5 million fractures
each year and is the primary underlying cause of fractures
in the elderly [3].
Both raloxifene and bisphosphonates are indicated for the
prevention and treatment of postmenopausal osteoporo-
sis. Raloxifene increases vertebral BMD and reduces the
risk of vertebral fractures in postmenopausal women with
and without preexisting vertebral fractures [4,5] but has
not been shown to reduce the risk of nonvertebral frac-
tures in patients versus placebo. However, studies of the
efficacy of raloxifene in reducing the incidence of nonver-
tebral fractures were not adequately powered to determine
whether this agent might also reduce the incidence of less
frequent nonvertebral fractures [4]. Bisphosphonates
reduce the risk of vertebral fractures, and two of the ami-
nobisphosphonates (i.e., alendronate and risedronate)
have been shown to reduce the risk of nonvertebral frac-
tures [6,7].
The relative efficacy of raloxifene and bisphosphonates
must be considered alongside the safety profiles associ-
ated with each treatment. The most common adverse
events associated with raloxifene are hot flushes and leg
cramps [8]. In addition, raloxifene has been associated
with a two-fold increase in venous thromboembolism [9].
Data from clinical trials suggest that raloxifene reduces the
risk of invasive breast cancer in postmenopausal women
[9-12] and in 2007, raloxifene received approval from the
FDA for reduction in risk of invasive breast cancer in post-
menopausal women with osteoporosis and in postmeno-
pausal women at high risk for invasive breast cancer [13].
The Raloxifene Use for the Heart (RUTH) trial, which was
conducted with women at high risk of coronary events,
indicated that there was no difference in overall mortality,
cardiovascular mortality, or overall number of strokes ver-
sus placebo, however there was an increased risk of fatal
stroke [12]. Thus, the risk benefit profile of raloxifene
should be considered in women at risk for stroke. The
most common adverse events associated with bisphos-
phonates are GI-related and include esophageal ulcera-
tion, stricture, and bleeding [14]. Osteonecrosis of the
jaw, generally associated with tooth extraction and/or
local infection has been reported in patients taking
bisphosphonates. Most reported cases of bisphospho-
nate-associated osteonecrosis have been in cancer patients
treated with intravenous bisphosphonates, but some have
occurred in patients with postmenopausal osteoporosis
[15-18].
Given the differing efficacy and safety profiles exhibited
by raloxifene and the bisphosphonates, it is plausible that
physicians would target these agents in such a way as to
optimize the corresponding benefit/risk profile for indi-
vidual patients. To explore this hypothesis, we sought to
describe and compare the demographic and clinical char-
acteristics of patients who initiate raloxifene therapy rela-
tive to patients initiating treatment with
bisphosphonates.
Methods
This study was conducted using a retrospective cohort
design. Data are from MarketScan® claims databases from
Thomson Reuters, which reflect the healthcare experience
of 62.1 million cumulative lives covered by a variety of
private health plans, as well as Medicare supplemental
and Medicaid insurance. Individuals with Medicare cover-
age are Medicare-eligible retirees with employer-spon-
sored Medicare Supplemental plans. Service claims during
the period January 2002 through June 2005 were assessed
for the commercial- and Medicare-insured populations,
which were combined for analysis. Due to limited data
availability, only service claims between January 1, 2002
and December 30, 2004 for Medicaid enrollees were
examined. These data sources contain the pooled health-
care experience of enrollees and include records of inpa-
tient services, inpatient admissions, outpatient services,
and prescription drug claims. The patient data used in this
analysis have been de-identified in compliance with
Health Insurance Portability and Accountability Act
(HIPAA) regulations, and, therefore, the study is exempt
from Institutional Review Board approval.
The study population consists of women aged 45 and
older who newly initiated treatment with raloxifene or a
bisphosphonate (i.e., alendronate, ibandronate, and rise-
dronate) any time during the period January 2003
through December 2005 (June 2004 for Medicaid). The
date of the first prescription claim for raloxifene or a
bisphosphonate in these periods represents the index date
for each patient. Because the focus of this study is on new
users, patients with a prescription for any osteoporosis
treatment during the pre-period were excluded from the
study. Patients were excluded if they had either an ICD-9
code or osteoporosis medication and dose indicative of
Paget's disease. Patients were also excluded if they did not
have prescription coverage in the pre- and post periods, or
the index prescription was coded with a days supply of 0
or of more than 180 days, presumably in error.
Measures
Demographic variables were defined as of the date of the
index prescription claim and include age, race (for Medic-
aid patients only), regional location, urban/rural resi-
dence, and health plan type (i.e., capitated versus non-BMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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capitated). Clinical characteristics and conditions thought
to potentially influence treatment choice were examined
using ICD-9-CM codes for diagnoses, CPT codes for pro-
cedures (e.g., bone mineral density [BMD] scans, mam-
mograms) and NDC codes for prior medication use. All
codes used to identify confounding conditions are pro-
vided in Appendix A [see Additional File 1].
Fractures in the pre-period were captured using Health
Plan Employer Data and Information Set (HEDIS) criteria
and are identified as either hip, vertebral, or other non-
vertebral (i.e., fractures of the extremities or ribs) [19].
HEDIS measurement guidelines were also used to identify
patients who received a bone mineral density (BMD) test
in the pre-period.
The Charlson Comorbidity Index (CCI) was calculated in
the pre-period as a proxy for overall health status [20].
Finally, the numbers of inpatient, emergency room, out-
patient, and pharmaceutical claims were evaluated for the
pre-period.
The specialty of the provider most closely associated with
the index prescription was also captured using an indirect
method given that provider identifiers are not available
on the prescription claims. The provider was determined
by examining all claims for "evaluation and manage-
ment" office visits in the 60 days prior to the index date.
Claims with an osteoporosis diagnosis were scanned first
to find the claim most temporally proximal to the pre-
scription. If no claim with an osteoporosis diagnosis was
found, then all claims in the 60-day period were scanned
to identify the one closest to the prescription date. Pro-
vider specialty was coded as specialist (including OB/
Gyn), or other (including primary care).
Analysis
Statistical tests of significance of differences between
groups were performed using chi-square tests for categor-
ical measures and Wilcoxon rank-sum tests for continu-
ous variables. Logistic regression was used to
simultaneously examine the factors independently associ-
ated with raloxifene use as opposed to bisphosphonate
use. Adjusted odds ratios and 95% confidence intervals
are presented for all model covariates. All data are shown
separately for individuals with commercial/Medicare
insurance and those with Medicaid.
Results
Prescription claims data were searched to identify the first
claim for raloxifene or a bisphosphonate between January
2003 and December 2004 for patients. In the commercial/
Medicare data 102,750 people had a claim for raloxifene
and 356,145 had a claim for a bisphosphonate. For those
receiving Medicaid there were 42,770 patients with a
raloxifene claim and 184,193 with a bisphosphonate
claim. The exclusion criteria having the greatest impact on
the sample size were the requirements of not having an
osteoporosis treatment in the pre-period and having con-
tinuous eligibility for 18 months. The final sample sizes
were 17,983 raloxifene and 79,891 bisphosphonate users
in the commercial/Medicare cohort and 11,504 raloxifene
and 59,881 bisphosphonate users in the Medicaid cohort.
Sample sizes following the application of exclusion crite-
ria are provided in Appendix B [see Additional File 2].
Columns two and three of Table 1 present the demo-
graphic characteristics of the combined commercial/
Medicare cohort. On average, patients initiating
raloxifene were younger than those initiating bisphospho-
nate treatment (mean age = 62.2 and 64.2, respectively).
Variation in the location of residence was also observed
between raloxifene and bisphosphonate initiators, with
higher proportions of raloxifene users residing in the
South and in non-urban areas relative to bisphosphonate
users. Finally, patients initiating raloxifene were more
likely to have seen a specialist around the time of their
index prescription than were patients initiating treatment
with a bisphosphonate.
Demographic characteristics of the Medicaid population
are summarized in columns four and five of Table 1. As
with the commercial/Medicare cohort, raloxifene users in
the Medicaid population were significantly younger than
their counterparts initiating bisphosphonate treatment.
Variation in the racial/ethnic composition of the cohorts
was also observed. Specifically, a greater proportion of
raloxifene patients were Asian compared with bisphos-
phonate patients, whereas higher proportions of bisphos-
phonate patients were white, Hispanic, or African
American. As with the commercial/Medicare population,
raloxifene users with Medicaid were more likely to have
seen a specialty provider than those using a bisphospho-
nate.
Table 2 displays the pre-period clinical characteristics of
patients initiating raloxifene and bisphosphonates in
both the commercial/Medicare and Medicaid cohorts.
Patients initiating bisphosphonate treatment had slightly
higher CCI scores and were more likely to have had a pre-
period fracture than patients initiating raloxifene. Further-
more, raloxifene users less frequently had a BMD test or
mammogram in the 12-month pre-period as compared to
patients initiating bisphosphonate treatment. A much
smaller proportion of Medicaid patients had a BMD
screen relative to patients in the commercial/Medicare
cohort.
Of the comorbid conditions evaluated, the most prevalent
among both raloxifene and bisphosphonate patients inBMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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the commercial/Medicare cohort were metabolic disor-
ders, cancer other than breast or bone, and endocrine dis-
ease. Patients who initiated raloxifene within this
insurance group were less likely to have breast cancers,
nephritis, rheumatoid arthritis, thyroid disease, oste-
oporosis, metabolic disorders and cardiovascular disease
than those who initiated bisphosphonate treatment. The
most prevalent comorbid conditions among patients in
both treatment groups within the Medicaid cohort were
metabolic disorders, endocrine disease, and cardiovascu-
lar disease. Among the Medicaid patients, those who ini-
tiated raloxifene were less likely to have breast cancer,
nephritis, osteoporosis and rheumatoid arthritis, but
more likely to have metabolic disorders than Medicaid
patients initiating a bisphosphonate. Gastrointestinal dis-
orders affected less than 1% of patients in all cohorts with
the exception of gastroesophageal reflux and gastritis,
which were noted in 2–3% of Medicaid recipients on
either a bisphosphonate or raloxifene.
In general, in both the commercial/Medicare and Medic-
aid groups, patients who initiated bisphosphonates were
more likely to be taking a medication associated with
bone complications than patients who initiated
raloxifene. Approximately 13% of patients initiating ther-
apy with raloxifene in the commercial/Medicare and Med-
icaid cohorts had a prescription for a glucocorticoid in the
pre-period, compared to approximately 16% among
patients initiating treatment with a bisphosphonate.
However, a greater proportion of patients initiating
raloxifene in the commercial/Medicare and Medicaid
groups had previous or concurrent use of estrogen/hor-
mone replacement therapy (HRT) within the past year
compared to patients initiating bisphosphonate treat-
Table 1: Demographic characteristics (Commercial/Medicare and Medicaid)
Commercial/Medicare Medicaid
Raloxifene Bisphosphonates Raloxifene Bisphosphonates
(N = 17,983) (N = 79,891) (N = 11,504) (N = 59,881)
Age (Mean, std.)* 62.2 (9.0) 64.2 (10.7) 69.3 (11.1) 71.8 (10.8)
Age group* %%%%
45–64 69.0 59.8 32.3 23.7
65–74 19.5* 20.2* 34.2* 34.0*
75 and over 11.5 20.0 33.5 42.2
Race *
White --- --- 33.9 39.9
African American --- --- 5.3 6.2
Hispanic/Latino --- --- 15.1 17.2
Asian --- --- 29.6 21.4
Other --- --- 16.1 15.3
Medicare* 26.6 36.7 --- ---
Location*
North East 7.3 10.7 --- ---
North Central 34.0 32.9 --- ---
South 46.1 38.5 --- ---
West 12.2 17.7 --- ---
Unknown 0.4 0.3 --- ---
Urban residence* 72.1 78.2 89.4 90.7
Insurance type*1
Indemnity 34.5 39.3 82.3 82.3
PPO 44.7 40.8 --- ---
Other 20.8 19.9 17.7 17.7
Provider specialty*
Specialist2 18.8 16.8 6.5 4.9
*Test for differences between raloxifene and bisphosphonates statistically significant at p < 0.0001
1 Difference not statistically different (p < 0.05) for Medicaid comparison
2 Specialist versus primary care or otherBMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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ment. Raloxifene users in both insurance groups were less
likely to have taken immunosuppressants or to have had
hormone deprivation therapy.
With regard to resource utilization, patients initiating a
bisphosphonate in both the commercial/Medicare and
Medicaid cohorts had more inpatient, emergency room,
outpatient, and prescription claims during the 12-month
study period than patients initiating raloxifene.
Table 2: Pre-period clinical characteristics (Commercial/Medicare, and Medicaid)
Commercial/Medicare Medicaid
Raloxifene Bisphosphonates Raloxifene Bisphosphonates
(N = 17,983) (N = 79,891) (N = 11,504) (N = 59,881)
Health status Mean (STD) Mean (STD) Mean (STD) Mean (STD)
CCI 0.5(1.1)* 0.7 (1.4) 0.9 (1.5)* 1.1 (1.6)
%%%%
Any fracture 10.0* 14.6 9.4* 14.2
Hip 0.4* 1.3 0.6* 1.3
Vertebral 1.4* 2.6 1.5* 2.4
Non-vertebral 9.2* 13.3 8.5* 12.7
Screening
BMD test 43.2* 63.8 20.9* 27.6
Mammogram 8.4* 10.6 8.7 9.2
Confounding conditions
Breast cancer 3.5* 5.5 6.0* 6.9
Endocrine disease 13.9 13.8 20.3 20.8
HIV 0.0 0.0 0.1 0.1
Liver disease 1.9 1.9 3.6 3.2
Bone cancer 0.0†† 0.1 0.0 0.0
Other cancer 20.1 21.5 10.3 10.6
Alcoholism 0.1 0.1 0.1 0.1
Osteodystrophy 0.0 0.1 0.1 0.1
Nephritis 0.8* 1.1 1.9† 2.4
Rheumatoid arthritis 1.5* 2.7 2.4* 3.7
Any cardiovascular disease 5.9* 8.1 13.1 13.1
Thyroid disease 11.5* 12.6 8.3 7.9
Metabolic disorders 30.9† 29.7 25.5* 23.4
Osteoporosis 2.9* 6.9 5.3* 8.0
DVT/PE 0.0* 0.1 0.2† 0.4
Gastric ulcer 0.1 0.1 0.3 0.3
Peptic ulcer 0.1 0.0 0.6 0.5
Dysphagia 0.2 0.3 0.6 0.6
Gastroesophageal reflux 0.9 1.0 2.4 2.1
Gastritis 0.3 0.4 2.9* 2.2
Medications
Glucocorticoids 13.4* 16.4 13.3* 16.6
Estrogen/HRT 38.4* 27.9 21.9* 13.7
Hormone deprivation therapy 1.2* 2.9 0.7* 1.6
Anticonvulsants 2.4* 3.1 5.4 5.8
Immunosuppressants 1.4* 2.6 1.1* 2.2
Resource utilization Mean (STD) Mean (STD) Mean (STD) Mean (STD)
Inpatient claims 0.1 (0.4)* 0.2 (0.5) 0.1 (0.5)* 0.1 (0.6)
ER claims 0.5 (2.0)* 0.6 (2.5) 2.1 (7.1)* 2.4 (8.4)
Outpatient claims 31.1 (32.7)* 36.4 (41.9) 49.0 (65.6)* 51.7 (70.3)
Rx claims 24.5 (24.9)* 26.2 (27.0) 46.9 (40.8) 49.9 (40.6)
Comparisons of raloxifene to bisphosphonates are statistically significant at: *p < 0.0001; †p < 0.001; †† p < 0.01BMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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Adjusted odds ratios for factors associated with use of
raloxifene relative to a bisphosphonate are shown in
Table 3. Among patients with commercial/Medicare
insurance, those under age 65 and over age 75 were less
likely to receive raloxifene relative to those between age 65
and 74. Among Medicaid recipients, however, the young-
est cohort (age 45–64) was more likely than those age 65–
74 to receive raloxifene. Non-white race/ethnicity was
associated with a greater likelihood of receiving raloxifene
among Medicaid recipients. For both insurance groups,
seeing a specialty provider as opposed to a primary care or
other physician was associated with increased odds of
receiving raloxifene. Factors associated with a lower likeli-
hood of receiving raloxifene and thus an increased likeli-
hood of receiving a bisphosphonate include higher CCI,
any prior fracture, pre-period BMD screening, a history of
breast cancer (commercial/Medicare only) and DVT/PE
and prior use of glucocorticoids. While a diagnosis of gas-
tric ulcer in the pre-period increased the odds of receiving
raloxifene among commercial/Medicare patients, it had
no effect on whether Medicaid patients received raloxifene
or a bisphosphonate, even though gastric ulcers were
more common among Medicaid recipients (see Table 2).
For both insurance groups, having received estrogen or
other hormone replacement therapy in the pre-period was
associated with greater odds of receiving raloxifene, how-
ever, glucocorticoid use in the pre-period was associated
with greater odds of receiving bisphosphonates.
Discussion
To date, our knowledge of the types of patients who initi-
ate raloxifene for the prevention and treatment of oste-
oporosis has been limited. Using data from a large
national commercial, Medicare, and Medicaid claims
database, this study addresses this gap by describing the
characteristics of patients who initiate raloxifene therapy.
For comparison, we also report the characteristics of
patients initiating therapy with a bisphosphonate.
The results of this study show demographic and clinical
differences between patients in the two treatment groups.
Patients initiating raloxifene therapy were younger and
had a lower burden of comorbid illness than patients ini-
tiating bisphosphonate therapy. Within both the com-
mercial/Medicare and Medicaid cohorts, patients
initiating raloxifene were also less likely to have had a
fracture or a BMD screen in the pre-period than patients
initiating bisphosphonate therapy. These differences
remained statistically significant in the multivariate
model. Patients initiating raloxifene may be more likely to
have been prescribed therapy for the prevention, rather
than the treatment, of osteoporosis as suggested by their
younger age relative to those using bisphosphonates as
well as being less likely to have had a diagnosis of oste-
oporosis or fractures in the pre-period. Cadarette et al.
reported that in a study population comprised of Medi-
care beneficiaries enrolled in statewide pharmaceutical
benefit plans, raloxifene patients were younger and had a
lower prevalence of fractures and comorbid conditions
compared to patients on alendronate or risedronate [21].
Raloxifene patients also had a lower prevalence of diag-
nosed osteoporosis documented in Medicare claims than
alendronate and risedronate recipients [21].
Prior or concomitant use of HRT was more common with
raloxifene patients, which might imply that physicians
consider raloxifene a treatment option when patients have
or will be discontinuing HRT. Medicaid patients in both
treatment groups had more claims of all types than
patients in the commercial/Medicare cohort, however, a
much smaller proportion of patients in the Medicaid
cohort had a BMD test. This indicates a lack of osteoporo-
sis screening which may result in underdiagnosis and
undertreatment of osteoporosis within the Medicaid pop-
ulation. Differences in the racial/ethnic compositions of
the treatment groups were also observed within the Med-
icaid population. A higher proportion of raloxifene users
were Asian while higher proportions of whites, Hispanics,
and African Americans initiated bisphosphonate treat-
ment. Additional research should be conducted to explore
these differences further, however, it may suggest differ-
ences in the cultural acceptance of SERM use or differ-
ences in perceptions of breast cancer risk which may result
in these disparities.
Differences in the clinical characteristics of patients initi-
ating raloxifene and bisphosphonates may be related to
the comparative efficacy and safety profiles of the two
treatments. For example, because the efficacy of raloxifene
to reduce the risk of non-vertebral fractures has not been
demonstrated in randomized, controlled trials, clinicians
may be more likely to prescribe it for osteopenic patients
or patients with less severe osteoporosis. Physicians may
be less likely to prescribe raloxifene in older patients due
to the increased risk of venous thromboembolism associ-
ated with its use. On the other hand, clinicians may be
more inclined to use raloxifene in certain patients, for
example younger women with a relatively low risk of non-
vertebral fracture and DVT/PE, or those with risk factors
for breast cancer.
While this study provides important insight into the dif-
ferences between patients who initiate raloxifene and
bisphosphonates for the prevention and treatment of
osteoporosis, a few limitations should be noted. First, as
with all claims data, available information is limited and
relies on the coding decisions, for billing purposes, of a
variety of professionals [22]. As such, the potential for
coding errors or omissions should be recognized. Further-
more, it is not possible to directly assess the primary med-BMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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Table 3: Multivariate logistic regression results for characteristics associated with raloxifene vs. bisphosphonate use
Commercial/Medicare Medicaid
Odds Ratio1 95% CI Odds Ratio1 95% CI
Age group
45–64 0.881 0.810–0.957 1.509 1.431–1.592
65–74 REFERENCE --- REFERENCE ---
75 and over 0.686 0.644–0.730 0.813 0.774–0.854
Race
White --- --- REFERENCE ---
African American --- --- 1.025 0.933–1.126
Hispanic/Latino --- --- 1.070 1.005–1.140
Asian --- --- 1.758 1.665–1.856
Other --- --- 1.299 1.220–1.382
Medicare 0.689 0.630–0.754 --- ---
Location
North East 0.672 0.629–0.718 --- ---
North Central 0.935 0.898–0.973 --- ---
South REFERENCE --- --- ---
West 0.642 0.609–0.678 --- ---
Urban residence 0.819 0.788–0.851 0.667 0.611–0.706
Insurance type
Indemnity 0.986 0.935–1.040 1.128 1.068–1.192
PPO 1.031 0.985–1.079 --- ---
Other REFERENCE --- REFERENCE ---
Provider specialty
Primary care/Other REFERENCE --- REFERENCE ---
Specialist 1.108 1.060–1.158 1.264 1.160–1.377
Health status
CCI 0.941 0.926–0.957 0.962 0.948–0.976
Fracture
Hip 0.449 0.350–0.577 0.659 0.507–0.856
Vertebral 0.664 0.580–0.762 0.744 0.631–0.876
Non-vertebral 0.803 0.758–0.851 0.726 0.674–0.781
BMD test 0.412 0.398–0.426 0.664 0.628–0.703
Mammogram 0.968 0.909–1.031 0.953 0.886–1.026
Confounding conditions
Breast cancer 0.746 0.679–0.819 1.021 0.928–1.123
DVT/PE 0.470 0.245–0.903 0.672 0.438–1.028
Gastric ulcer 2.273 1.181–4.375 0.861 0.585–1.267
Peptic ulcer 2.048 0.964–4.353 1.228 0.942–1.601
Dysphagia 0.974 0.694–1.367 1.200 0.917–1.571
Reflux 1.080 0.897–1.300 1.156 1.005–1.329
Gastritis 0.904 0.666–1.228 1.316 1.156–1.499
Osteoporosis 0.632 0.573–0.697 0.818 0.745–0.898
Medications
Glucocorticoids 0.774 0.737–0.813 0.757 0.713–0.804
Estrogen/HRT 1.325 1.279–1.372 1.501 1.426–1.581
1Odds ratios that are less than 1.0 indicate that the covariate is associated with a lower likelihood of receiving raloxifene (or is associated with 
equivalently a higher likelihood of receiving a bisphosphonate). Odds ratios greater than 1.0 indicate that the covariate is associated with a higher 
likelihood of receiving raloxifene.BMC Women's Health 2008, 8:24 http://www.biomedcentral.com/1472-6874/8/24
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ical condition (e.g., osteoporosis) prompting a particular
prescription, much less the true motivation (in the mind
of the prescriber) leading to selection of one agent over
another.
It should also be noted that the Medicare patients
included in this study are those with supplemental insur-
ance provided by employers. Because the characteristics
and experiences of patients with Medicare coverage alone
may differ from patients with supplemental insurance, the
extent to which our results are generalizable to the entire
Medicare population is unclear. Finally, medication for-
mulary status was unavailable. Therefore, it is unclear how
formulary placement may have impacted treatment pat-
terns.
Conclusion
The findings of this study suggest that patients initiating
raloxifene for the prevention and treatment of osteoporo-
sis differ from those initiating bisphosphonates. Patients
initiating raloxifene tend to be younger, have better over-
all health status and may have fewer risk factors for new
osteoporotic fractures than patients initiating bisphos-
phonates. Differences in the clinical profiles of these med-
ications may impact prescribing decisions. Investigators
using observational data to make comparisons of treat-
ment outcomes associated with these medications should
take these important differences in patient characteristics
into consideration.
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